🔗 Share this article

A shadow market for unlicensed weight-loss medications is propelled by social media fitness personalities and sellers on messaging platforms, based on recent findings.

Experimental Drug Gaining Traction Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Followers are encouraged to message these accounts directly for source information, while also obtaining discount codes.

Active Trade on Social Networks

Separately, a flourishing trade exists on Telegram, where groups with thousands of members share comparison photos, injection guides and assertions of next-day UK delivery. Sellers market the drug there before directing buyers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an investigational injection created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Medical Experts Express Concerns

Nevertheless, doctors and chemists have warned that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.

Several professionals said the popularity for the experimental drug could be connected to the increasing cost of approved weight loss products such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on TikTok or messaging apps is illegal in the UK, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers try to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still violate medicines, advertising, and customer laws, potentially leading to fines, legal action or prison.

Service Response and Material Removal

According to the social media company, the platform has taken down problematic material and prohibited associated keywords and search suggestions. The company said it was committed to maintaining the platform secure and investing in enhancing compliance measures.

Digital Marketplace Operations

Investigations also found groups with up to nine thousand members selling the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of users, populated with images of weight loss, glowing testimonials and detailed instructions for mixing or administering at home.

Within moments of entering one community, a vendor posted contact information, where most transactions occur. The vendor provided an guidebook and promised delivery within two days. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one asked about weight, health issues or past usage.

Product Information and Costs

Within these groups, posts display black plastic parcels with postal service stickers, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with sterile water, or pre-filled injectors typically sold at 160 pounds for 20mg. When asked how long a injector should be used, sellers give contradictory answers ranging from a several days to “depends on your body”.

Platform Oversight and Safety Actions

A spokesperson for Telegram said it actively monitored dangerous content on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting substances they cannot confirm. Although the science behind this drug is sound, these digital versions may not contain what they claim,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current cost increases for approved slimming medications such as Mounjaro. “With costs rising, patients are turning to online platforms. But fake injections are extremely dangerous. You cannot know what’s inside or whether the environment they were produced in was clean,” she explained.

Her team has previously seen patients harmed by personal administration from unverified sources. “We understand the frustration, but buying from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These substances could be impure or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly stated the substance was in third stage research studies and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose users to possibly serious medical dangers”.